Skip to main content
DYN
NASDAQ Life Sciences

Director Jason Rhodes Sells $65.2M in Dyne Stock via 10b5-1 Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$26.15
Mkt Cap
$4.883B
52W Low
$11.645
52W High
$27.305
52W Position info
125% above low
Off High info
4.2% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $11.645.

Summary

Director Jason Rhodes sold $65.2 million of Dyne Therapeutics stock under a pre-arranged 10b5-1 trading plan, reducing his indirect holdings while retaining a substantial position.


Key Events · Ownership and Investor Activity · DYN

  • Director Sells $65.2M in Stock

    Jason P. Rhodes sold 2,586,928 shares for $65,184,894.40 on August 13-14, 2026, at prices ranging from $25.00 to $26.20 per share.

  • 10b5-1 Plan Execution

    The sales were executed under a Rule 10b5-1 trading plan adopted on July 13, 2026, indicating the transactions were pre-planned rather than discretionary.

  • Post-Sale Holdings

    Rhodes retains 3,801,128 shares indirectly through various Atlas Venture funds, representing a substantial ongoing stake in the company.

  • Near 52-Week High

    The sales occurred with the stock trading near its 52-week high of $27.31, suggesting the insider capitalized on recent price strength.


Analysis · DYN · Life Sciences

A significant insider sale at Dyne Therapeutics has just been disclosed. Director Jason P. Rhodes sold 2,586,928 shares for $65.2 million on August 13-14, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted July 13, 2026. The transactions occurred near the stock's 52-week high of $27.31, with prices ranging from $25.00 to $26.20. While the sales are substantial, they were executed under a pre-planned trading arrangement, which reduces the signal of insider conviction. Rhodes retains 3,801,128 shares, indicating a continued stake. The company recently completed a $375 million follow-on offering and received FDA Priority Review for its lead candidate, providing context for the stock's strength.

At the time of this filing, DYN was trading at $26.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $11.65 to $27.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $26.15 info
Change: +$0.2069 (+0.80%) info
Market Cap: $4.883B info
DYN
Jul 29, 2026, 4:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $24.81
Real-time Price: $26.15 info
Change: +$1.34 (+5%) info
Market Cap: $4.883B info
DYN
Jul 29, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.81
Real-time Price: $26.15 info
Change: +$1.34 (+5%) info
Market Cap: $4.883B info
DYN
Jul 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $25.88
Real-time Price: $26.15 info
Change: +$0.274 (+1%) info
Market Cap: $4.883B info
DYN
Jul 22, 2026, 5:21 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $23.21
Real-time Price: $26.15 info
Change: +$2.94 (+13%) info
Market Cap: $4.883B info